We are proposing the creation of a Mental Health Clinical Research Center (MHCRC) in Schizophrenia Studies to replace our current Developing Clinical Research Center (DCRC). This section serves as an introduction to the MHCRC proposal. Our DCRC has now been in place for three and one half years. In that time we have focused our attention on our original aim,. To examine the contributions of genetic and epigenetic (or environmental risk) factors in schizophrenia etiology. We have also met another of our original goals and established a significant neuroimaging component to our Center. Finally, we have established strengths in diagnosis, phenomenology, neuroimmunology, neuropathology, and molecular biology. We now believe that we are now in an excellent position to link neuroimaging and neurobiological research to genetics and epidemiology of schizophrenia. In this way, we hope to make systematic observations that establish both likely etiological factors occurring from prenatal life and their specific relationship to biological abnormalities in adults who develop schizophrenia. The proposed MHCRC will have five cores: 1) Administrative, Biostatistical and Data Management; 2) Diagnosis and Treatment Research Core (DIRC); 3) Neurodevelopmental and Genetic Epidemiology Research Core (NGRC); 4) Brain Imaging Research Core (BIRC); and 5) Genomics and Neurobiology Research Core (GNRC). Each core will be responsible for supporting critical Center-wide needs and for conducting Core-specific research. Many of these functions require MHCRC support including the provision of standardized research-quality diagnoses and assessments that can be used across projects; the ability to maintain patients in a medication-free state and to recruit medication-naive subjects; the maintenance of several large birth cohorts; and the provision of state-of-the-art neuroimaging and laboratory facilities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Center Core Grants (P30)
Project #
5P30MH059342-02
Application #
6186349
Study Section
Clinical Centers and Special Projects Review Committee (CCSP)
Program Officer
Zalcman, Steven J
Project Start
1999-09-30
Project End
2002-08-31
Budget Start
2000-09-01
Budget End
2001-08-31
Support Year
2
Fiscal Year
2000
Total Cost
$738,634
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Goetz, Raymond R; Corcoran, Cheryl; Yale, Scott et al. (2007) Validity of a 'proxy'for the deficit syndrome derived from the Positive And Negative Syndrome Scale (PANSS). Schizophr Res 93:169-77
Kimhy, David; Yale, Scott; Goetz, Raymond R et al. (2006) The factorial structure of the schedule for the deficit syndrome in schizophrenia. Schizophr Bull 32:274-8
Kayser, Jurgen; Tenke, Craig E (2006) Principal components analysis of Laplacian waveforms as a generic method for identifying ERP generator patterns: I. Evaluation with auditory oddball tasks. Clin Neurophysiol 117:348-68
Kayser, Jurgen; Tenke, Craig E (2006) Principal components analysis of Laplacian waveforms as a generic method for identifying ERP generator patterns: II. Adequacy of low-density estimates. Clin Neurophysiol 117:369-80
van Berckel, Bart N M; Kegeles, Lawrence S; Waterhouse, Rikki et al. (2006) Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography. Neuropsychopharmacology 31:967-77
Slifstein, Mark; Hwang, Dah-Ren; Huang, Yiyun et al. (2004) In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Psychopharmacology (Berl) 175:274-86
Waterhouse, Rikki N; Slifstein, Mark; Dumont, Filip et al. (2004) In vivo evaluation of [11C]N-(2-chloro-5-thiomethylphenyl)-N'-(3-methoxy-phenyl)-N'-methylguanidine ([11C]GMOM) as a potential PET radiotracer for the PCP/NMDA receptor. Nucl Med Biol 31:939-48
Huang, Yiyun; Hwang, Dah-Ren; Bae, Sung-A et al. (2004) A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM). Nucl Med Biol 31:543-56
Harkavy-Friedman, Jill M; Nelson, Elizabeth A; Venarde, David F et al. (2004) Suicidal behavior in schizophrenia and schizoaffective disorder: examining the role of depression. Suicide Life Threat Behav 34:66-76
Brown, Alan S; Hooton, Jonathan; Schaefer, Catherine A et al. (2004) Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry 161:889-95

Showing the most recent 10 out of 30 publications